The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | An update on the Phase II/III IMerge trial of imetelstat in LR-MDS
Valeria Santini, MD, University of Florence, Florence, Italy, discusses updates from the Phase II/III IMerge trial (NCT02598661), which explored imetelstat as a treatment for lower-risk myelodysplastic syndromes (LR-MDS). The results from the trial were impressive, with 40% of patients achieving the primary endpoint of transfusion independence for longer than 8 weeks. She discusses other findings and emphasizes the importance of further evaluation to better understand the drug’s mechanisms. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
